EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY-NC 4.0

Effect of Dapagliflozin on Measured vs. Panel‐Estimated Glomerular Filtration Rate

Esben Iversen iD, Line Juel Nielsen, Viktor Rotbain Curovic iD, Anne Byriel Walls iD, Mie Klessen Eickhoff iD, Marie Frimodt-Møller iD, Frederik Persson iD, Peter Rossing iD, Morten Baltzer Houlind iD

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.3480 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Esben Iversen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Research, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark. Hauptthemen laut MEDLINE: Glomerular Filtration Rate, Benzhydryl Compounds, Glucosides, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sodium–glucose cotransporter 2 (SGLT2) inhibitors can cause a reversible decline in glomerular filtration rate (GFR), which may influence dosing recommendations for renally excreted medications. In practice, GFR is typically estimated by serum creatinine concentration, but creatinine may not be a reliable indicator of GFR decline in the setting of SGLT2 inhibitor use. Alternative filtration markers such as cystatin C, β‐trace protein (BTP), and β2‐microglobulin (B2M) may be more appropriate, but little is known about how these markers are affected by SGLT2 inhibitor use. Therefore, we determined creatinine, cystatin C, BTP, and B2M concentration in a crossover study of 35 people with type 2 diabetes receiving 12 weeks of dapagliflozin treatment or placebo. Estimated GFR (eGFR) based on creatinine (eGFRcre), cystatin C (eGFRcys), their combination (eGFRcomb), or a panel of all four markers (eGFRpanel) was compared with measured GFR (mGFR) based on plasma clearance of chromium‐51 labeled ethylenediamine tetraacetic acid ( 51 Cr‐EDTA). Dapagliflozin treatment was associated with a significant decrease in mGFR (−9 mL/min/1.73 m 2 , P < 0.001) but not a corresponding increase in concentration of any filtration marker. No eGFR equation accurately predicted change in mGFR between treatment periods, but eGFRcomb and eGFRpanel yielded the highest overall accuracy relative to mGFR across both treatment periods. These findings highlight the stability in performance gained by combining multiple filtration markers but suggest that eGFR in general is not an ideal metric for assessing short‐term GFR decline in people initiating SGLT2 inhibitor therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerular Filtration RateBenzhydryl CompoundsGlucosidesSodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2HumansMaleFemaleMiddle AgedCross-Over StudiesAgedCreatinineCystatin CBiomarkersbeta 2-MicroglobulinDouble-Blind MethodIntramolecular OxidoreductasesLipocalins

Substanzen

Benzhydryl CompoundsdapagliflozinGlucosidesSodium-Glucose Transporter 2 InhibitorsCreatinineCystatin CBiomarkersbeta 2-Microglobulinprostaglandin R2 D-isomeraseB2M protein, human

Autor:innen und Institutionen

  • Department of Clinical Research, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark.
  • Northwell, New Hyde Park, New York, USA.
  • Steno Diabetes Center Copenhagen, Herlev, Denmark.
  • The Capital Region Pharmacy, Herlev, Denmark.
  • Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: Esben Iversen, Viktor Rotbain Curovic, Anne Byriel Walls, Mie Klessen Eickhoff, Marie Frimodt-Møller, Frederik Persson, Peter Rossing, Morten Baltzer Houlind

Zitieren

APA

Iversen, E., Nielsen, L. J., Curovic, V. R., Walls, A. B., Eickhoff, M. K., Frimodt-Møller, M., Persson, F., Rossing, P., & Houlind, M. B. (2025). Effect of Dapagliflozin on Measured vs. Panel‐Estimated Glomerular Filtration Rate. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3480

Vancouver

Iversen E, Nielsen LJ, Curovic VR, Walls AB, Eickhoff MK, Frimodt-Møller M, et al. Effect of Dapagliflozin on Measured vs. Panel‐Estimated Glomerular Filtration Rate. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3480

BibTeX
@article{Iversen2025,
  author = {Iversen, Esben and Nielsen, Line Juel and Curovic, Viktor Rotbain and Walls, Anne Byriel and Eickhoff, Mie Klessen and Frimodt-Møller, Marie and Persson, Frederik and Rossing, Peter and Houlind, Morten Baltzer},
  title = {Effect of Dapagliflozin on Measured vs. Panel‐Estimated Glomerular Filtration Rate},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.3480}
}
Kostenlos starten →